Daiichi Sankyo is ready to write down 359.5 billion yen ($3.84 billion) valuation loss on its attainment of Ranbaxy Laboratories.
When Daiichi Sankyo, Japanese major had announced in June that it was buying controlling stake at Rs.737 a share, Ranbaxy’s shares are presently trading around Rs.250 on the BSE.
On a consolidated basis, the Japanese firm plans to log a loss of 354 billion yen in the third quarter through December due to the plunging stock market. Nevertheless, in a statement issued to the Tokyo Stock Exchange, Daiichi Sankyo said this would not have an impact on its forecasts for net sales, operating income or its cash flow for the third quarter fiscal.